Valeria Prada1, Federico Massa2, Alexander Salerno2, Davide Fregosi2, Alessandro Beronio3, Carlo Serrati4, Antonio Mannironi3, Giovanni Mancardi2,4, Angelo Schenone2, Luana Benedetti2. 1. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, RCCS Policlinico San Martino, University of Genova, Largo Daneo 3, 16132, Genoa, Italy. valeria.prada@gmail.com. 2. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, RCCS Policlinico San Martino, University of Genova, Largo Daneo 3, 16132, Genoa, Italy. 3. Department of Neurology, Sant'Andrea Hospital, La Spezia, Italy. 4. Department of Neurology, IRCCS Policlinico San Martino, Genoa, Italy.
Abstract
BACKGROUND: Guillain-Barrè syndrome (GBS) is often associated with a residual disability. Nonetheless, poor and incomplete studies have been published addressed towards the assessment of importance of physiotherapy (FKT) in the recovery. The aim of the study was to explore the effects of prolonged FKT associated with medical therapy and to evaluate the long-term outcome. METHODS: A retrospective analysis was carried out on patients with GBS who needed to continue rehabilitation after hospitalization and admitted to the Neurological Department of La Spezia from 2003 to 2017. MRC and GBS-Disability scale (GBS-DS) were performed at the time of greatest clinical disability, after medical therapy, and at the end of the overall FKT. The final outcome evaluation was based on the ability to walk with or without support. ANOVA with Bonferroni post-test were used to compare MRC and GBS-DS. RESULTS: Ninety-six patients were admitted, but only 51 satisfied inclusion criteria. Forty patients performed intensive treatment for an average of 60.95 days, and 31 of them, once discharged, are required to continue FKT as outpatients for a mean period of 96.45 days. The mean value of MRC and GBS-DS post-FKT improved significantly compared with the post-medical therapy. Concerning walking, among the 40 patients who did not walk before therapy, 8 need support after the medical therapy and 4 (11.76%) cannot walk independently at the last follow-up. CONCLUSIONS: In conclusion, FKT associated to medical therapy can improve the outcome of the disease, if performed for periods exceeding 6 months.
BACKGROUND: Guillain-Barrè syndrome (GBS) is often associated with a residual disability. Nonetheless, poor and incomplete studies have been published addressed towards the assessment of importance of physiotherapy (FKT) in the recovery. The aim of the study was to explore the effects of prolonged FKT associated with medical therapy and to evaluate the long-term outcome. METHODS: A retrospective analysis was carried out on patients with GBS who needed to continue rehabilitation after hospitalization and admitted to the Neurological Department of La Spezia from 2003 to 2017. MRC and GBS-Disability scale (GBS-DS) were performed at the time of greatest clinical disability, after medical therapy, and at the end of the overall FKT. The final outcome evaluation was based on the ability to walk with or without support. ANOVA with Bonferroni post-test were used to compare MRC and GBS-DS. RESULTS: Ninety-six patients were admitted, but only 51 satisfied inclusion criteria. Forty patients performed intensive treatment for an average of 60.95 days, and 31 of them, once discharged, are required to continue FKT as outpatients for a mean period of 96.45 days. The mean value of MRC and GBS-DS post-FKT improved significantly compared with the post-medical therapy. Concerning walking, among the 40 patients who did not walk before therapy, 8 need support after the medical therapy and 4 (11.76%) cannot walk independently at the last follow-up. CONCLUSIONS: In conclusion, FKT associated to medical therapy can improve the outcome of the disease, if performed for periods exceeding 6 months.
Authors: Nicholas Simatos Arsenault; Pierre-Olivier Vincent; Bai He Shen Yu; Robin Bastien; Aaron Sweeney Journal: Physiother Can Date: 2016 Impact factor: 1.037
Authors: Richard A C Hughes; Anthony V Swan; Jean-Claude Raphaël; Djillali Annane; Rinske van Koningsveld; Pieter A van Doorn Journal: Brain Date: 2007-03-02 Impact factor: 13.501
Authors: M P J Garssen; J B J Bussmann; P I M Schmitz; A Zandbergen; T G Welter; I S J Merkies; H J Stam; P A van Doorn Journal: Neurology Date: 2004-12-28 Impact factor: 9.910
Authors: Aloysius Niroshan Siriwardena; Joseph N A Akanuwe; Vanessa Botan; Despina Laparidou; Ffion Curtis; Jennifer Jackson; Zahid B Asghar; Timothy L Hodgson Journal: Health Expect Date: 2021-10-01 Impact factor: 3.377